After showing Wegovy cut cardiovascular risk by 20%, results detail impact on death and heart failure
Three months after a large study of Novo Nordisk’s popular weight-loss and diabetes injection showed it cut major cardiovascular risks by 20%, further results from the trial showed how the drug affected other crucial outcomes like heart failure and death.
Novo released topline data from the study in August, noting at that time that it planned to file for a label expansion in the US and EU this year. The vast SELECT trial, which enrolled 17,604 patients, is one of the largest and longest studies — 4 1/2 years — investigating the GLP-1 in adults. Participants were 45 years old or older, didn’t have diabetes, were overweight or obese, and had a diagnosis of cardiovascular disease. They got either a placebo, or 2.4 mg of semaglutide, which is approved as Wegovy for weight loss and Ozempic for type 2 diabetes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.